The nation of Zimbabwe has declined a major American healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's insistence on sensitive information.
The decision was revealed following a official document dated December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "skewed".
An official representative has since stated that the US was demanding access to genetic material for research and commercial purposes while refused to guarantee the resulting advantages from future medical innovations.
"We must now begin the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had donated over $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has appealed for continued dialogue to reach a agreement agreeable to all parties so the country's critical HIV programme can be sustained.
Wider Background
This rejection comes after a similar situation in neighbouring Kenya, where a high court blocked a similar deal with the US after concerns were raised about the security of citizens' health data.
Since resuming office recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had overseen aid for the US government, but Trump stated its spending was "inefficient" and his administration was pursuing direct bilateral agreements to boost openness and accountability.
Based on reports, Sixteen nations in Africa have to date signed these new health pacts, representing more than $18.3bn in committed funds.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership could have provided immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on HIV treatment via American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to share its genetic material and health information for a long time, with no corresponding assurance of access to any scientific breakthroughs – like new medicines or tests – that might result from that shared data," he stated.
"Put simply, our country would provide the raw materials for scientific discovery without any assurance that the end products would be accessible to our citizens if a future disease outbreak emerge."
Sovereignty and Global Health
He also said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending frameworks previously set up via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to deal with future global health emergencies.
"This mechanism is designed to ensure that when a nation provides its data, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the funds to develop them."
The government's concerns over the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage further discussions with our American counterparts on how subsequent co-operation might be designed in a manner that respects the independence and interests of both nations."
Health Experts Response
Medical experts stated it understood the government's concerns, but recommended that negotiations should continue given that a large portion of the country's Aids initiatives relied on external financing.
"Where technical issues arise, including those relating to information security or implementation frameworks, these can often be resolved through detailed discussion and negotiated safeguards," it added.
The situation underscores the continuing challenges between accepting crucial international aid and safeguarding national sovereignty in an ever more data-driven world.